Flag of the European Union EU Clinical Trials Register Help

Clinical trials for antibody

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,187 result(s) found for: antibody. Displaying page 191 of 260.
    «« First « Previous 187  188  189  190  191  192  193  194  195  Next» Last»»
    EudraCT Number: 2021-001587-13 Sponsor Protocol Number: RC21_0169 Start Date*: 2021-10-01
    Sponsor Name:CHU de Nantes
    Full Title: A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse.
    Medical condition: Elderly patients with multiple myeloma at first relapse
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004957-62 Sponsor Protocol Number: ET20-093 Start Date*: 2021-09-09
    Sponsor Name:Centre Léon Bérard
    Full Title: Immunotherapy in MSI/dMMR Tumors in perioperative setting
    Medical condition: MSI/dMMR tumors or EBV+ gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000727-41 Sponsor Protocol Number: GFPC062018 Start Date*: 2019-06-04
    Sponsor Name:Centre François Baclesse
    Full Title: A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGF...
    Medical condition: Patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004490-52 Sponsor Protocol Number: MK-1308A-004 Start Date*: 2021-03-19
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Partici...
    Medical condition: Advanced hepatocellular carcinoma without any prior systemic treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002594-28 Sponsor Protocol Number: APHP200036 Start Date*: 2022-10-05
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
    Full Title: Graft Acute kidney injury: vitamin B3 to facilitate renal Recovery In the Early Life of a transplant
    Medical condition: Patients with end-stage renal failure treated with extrarenal purification (hemodialysis using a catheter or a fistula, or peritoneal dialysis), registered on the national kidney donation waiting l...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003569-36 Sponsor Protocol Number: D9571C00001 Start Date*: 2022-04-01
    Sponsor Name:AstraZeneca AB,
    Full Title: A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with R...
    Medical condition: Relapse/Refractory Classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000101-28 Sponsor Protocol Number: AMB-051-07 Start Date*: 2022-12-08
    Sponsor Name:AmMax Bio, Inc.
    Full Title: A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects w...
    Medical condition: Tenosynovial Giant Cell Tumor
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004864 10084212 Pigmented villonodular synovitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012324-83 Sponsor Protocol Number: UZB-BN-09-001 Start Date*: 2009-07-04
    Sponsor Name:Prof Bart Neyns
    Full Title: CeCil: A randomized, non-comparative phase II clinical trial of the effect of radiation therapy plus Temozolomide combined with Cilengitide or Cetuximab on the 1-year overall survival of patients w...
    Medical condition: Subjects with newly diagnosed glioblastoma, who have met all eligibility criteria for the CENTRIC study (EMD 121974-011 study, EudraCT 2007-004344-78) with the exception of NOT having a tumor with ...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10018336 Glioblastoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006075-42 Sponsor Protocol Number: ALXN1210-NMO-317 Start Date*: 2022-05-17
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents Wit...
    Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002841-31 Sponsor Protocol Number: PEOPLE Start Date*: 2018-01-26
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (<50%)_ PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors)
    Medical condition: Advanced NSCLC patients with PD-L1 low tumors (<50%)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002340-90 Sponsor Protocol Number: HPV-Xneutra-001 Start Date*: 2013-06-26
    Sponsor Name:Ghent University Hospital
    Full Title: Study of the molecular mechanisms underlying the cross-neutralizing capacity of AS04-adjuvanted HPV vaccine (Cervarix®) in comparison with the aluminiumhydroxyphosphate sulphate adjuvanted HPV vacc...
    Medical condition: vaccin against the human papillomavirus
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10046859 Vaccination LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000765-20 Sponsor Protocol Number: ANTIVEGFVEP Start Date*: 2015-11-27
    Sponsor Name:Kuopion yliopistollinen sairaala/silmätautien poliklinikka
    Full Title: The Effect of Intravitreal Bevacizumab Injections in Patients with Macular Oedema Caused by AMD, CRVO or DME on the Plasticity of Nerves Studied by Visual Evoked Potentials
    Medical condition: Wet age-related macular degeneration, diabetic macular edema, central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10012675 Diabetic macular retinopathy LLT
    18.1 100000004853 10007972 Central retinal vein occlusion LLT
    18.1 100000004853 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004628-31 Sponsor Protocol Number: FIL_V-RBAC Start Date*: 2018-05-15
    Sponsor Name:Fondazione Italiana Linfomi ONLUS
    Full Title: Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)
    Medical condition: Mantle Cell Lymphoma in elderly patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001819-12 Sponsor Protocol Number: CIS-COV Start Date*: 2022-10-13
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Cysteamine in association with standard therapy for the treatment of hospitalized patients with COVID-19 pneumonia: phase 2 study on safety of a new antiviral and direct therapy on the host
    Medical condition: Covid-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000729-13 Sponsor Protocol Number: 2020_0068 Start Date*: 2021-01-21
    Sponsor Name:Hôpital Foch
    Full Title: Evaluation of Glucocorticoids plus Rituximab compared to Glucocorticoids plus Placebo for the treatment of patients with newly-diagnosed or relapsing IgA vasculitis : A prospective, randomized, con...
    Medical condition: Patients with a diagnosis of IgAV according to Chapel Hill Consensus Conference definitions. Patients will require having a biopsy-proven diagnosis of IgAV.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004330-15 Sponsor Protocol Number: D20180138 Start Date*: 2019-01-10
    Sponsor Name:Assistance Publique - Hôpitaux de Paris (AP-HP)
    Full Title: A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethasone for relapsed multiple myeloma
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10051381 Myeloma recurrence LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002829-28 Sponsor Protocol Number: B8011011 Start Date*: 2021-06-01
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: locally advanced or metastatic NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000569-18 Sponsor Protocol Number: RECHMPL20_0094 Start Date*: 2020-10-02
    Sponsor Name:University Hospital of Montpellier
    Full Title: NEOADUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MULTICENTER RANDOMIZED PHASE II TRIAL
    Medical condition: Digestive oncology
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000547-24 Sponsor Protocol Number: CCRG11-001 Start Date*: 2012-02-27
    Sponsor Name:Antwerp University Hospital
    Full Title: Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study
    Medical condition: Therapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000297-17 Sponsor Protocol Number: 69HCL19_0153 Start Date*: 2021-01-21
    Sponsor Name:Hospices Civils de Lyon
    Full Title: IMMUNOGAST: An umbrella phase 2 trial to assess personalized targeted IMMUNOtherapy-based regimens in recurrent advanced/metastatic GASTric adenocarcinoma patients
    Medical condition: For patients with advanced/metastatic gastric adenocarcinomas in progression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10071114 Metastatic gastric adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 187  188  189  190  191  192  193  194  195  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:24:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA